Connection

THOMAS MONATH to Mice

This is a "connection" page, showing publications THOMAS MONATH has written about Mice.
Connection Strength

0.607
  1. Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential. PLoS Pathog. 2022 06; 18(6):e1010658.
    View in: PubMed
    Score: 0.060
  2. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses. 2013 Dec 09; 5(12):3048-70.
    View in: PubMed
    Score: 0.033
  3. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine. 2010 May 14; 28(22):3827-40.
    View in: PubMed
    Score: 0.026
  4. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals. 2005 Sep; 33(3):131-44.
    View in: PubMed
    Score: 0.019
  5. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol. 2004 Nov; 78(22):12497-507.
    View in: PubMed
    Score: 0.018
  6. Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg. 2004 Nov; 71(5):639-45.
    View in: PubMed
    Score: 0.018
  7. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol. 2004 Sep; 78(18):9998-10008.
    View in: PubMed
    Score: 0.018
  8. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol. 2004 May; 78(9):4761-75.
    View in: PubMed
    Score: 0.017
  9. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
    View in: PubMed
    Score: 0.016
  10. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med. 2003 Sep; 9(9):1125-30.
    View in: PubMed
    Score: 0.016
  11. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2. Emerg Microbes Infect. 2022 Dec; 11(1):2724-2734.
    View in: PubMed
    Score: 0.016
  12. Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease. Am J Trop Med Hyg. 2022 11 14; 107(5):1091-1098.
    View in: PubMed
    Score: 0.015
  13. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology. 2002 Jun 20; 298(1):146-59.
    View in: PubMed
    Score: 0.015
  14. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol. 2002 Feb; 76(4):1932-43.
    View in: PubMed
    Score: 0.015
  15. Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent. Vaccine. 2001 Sep 14; 19(32):4883-95.
    View in: PubMed
    Score: 0.014
  16. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol. 2001 Aug; 75(16):7290-304.
    View in: PubMed
    Score: 0.014
  17. West Nile virus vaccine. Curr Drug Targets Infect Disord. 2001 May; 1(1):37-50.
    View in: PubMed
    Score: 0.014
  18. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000 Jun; 74(12):5477-85.
    View in: PubMed
    Score: 0.013
  19. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun. 2000 May; 68(5):2775-82.
    View in: PubMed
    Score: 0.013
  20. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol. 2000 Feb; 74(4):1742-51.
    View in: PubMed
    Score: 0.013
  21. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999 May 10; 257(2):363-72.
    View in: PubMed
    Score: 0.012
  22. Oral immunization with recombinant Helicobacter pylori urease confers long-lasting immunity against Helicobacter felis infection. Vaccine. 1999 Mar 17; 17(11-12):1394-403.
    View in: PubMed
    Score: 0.012
  23. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med. 1998 Dec 21; 188(12):2277-88.
    View in: PubMed
    Score: 0.012
  24. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immun. 1998 Jun; 66(6):2879-86.
    View in: PubMed
    Score: 0.011
  25. Vaccine development against infection with Helicobacter pylori. Br Med Bull. 1998; 54(1):229-41.
    View in: PubMed
    Score: 0.011
  26. Gastritis in urease-immunized mice after Helicobacter felis challenge may be due to residual bacteria. Gastroenterology. 1997 Oct; 113(4):1118-28.
    View in: PubMed
    Score: 0.011
  27. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis. 1996 Aug; 174(2):256-61.
    View in: PubMed
    Score: 0.010
  28. Antigenicity of amino-acid sequences from Clostridium difficile toxin B. J Med Microbiol. 1996 Jun; 44(6):464-74.
    View in: PubMed
    Score: 0.010
  29. Stability of yellow fever vaccine. Dev Biol Stand. 1996; 87:219-25.
    View in: PubMed
    Score: 0.010
  30. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis. 1995 Jul; 172(1):161-72.
    View in: PubMed
    Score: 0.009
  31. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob Agents Chemother. 1994 Dec; 38(12):2785-91.
    View in: PubMed
    Score: 0.009
  32. Oral administration of polymeric immunoglobulin A prevents colonization with Vibrio cholerae in neonatal mice. Infect Immun. 1994 Mar; 62(3):887-91.
    View in: PubMed
    Score: 0.008
  33. Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice. Vaccine. 2012 Jan 05; 30(2):254-64.
    View in: PubMed
    Score: 0.007
  34. Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE). Vaccine. 2007 Sep 17; 25(37-38):6661-71.
    View in: PubMed
    Score: 0.005
  35. A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus. Virology. 2007 Jun 05; 362(2):468-74.
    View in: PubMed
    Score: 0.005
  36. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine. 2004 Sep 09; 22(27-28):3722-6.
    View in: PubMed
    Score: 0.004
  37. Yellow fever monoclonal antibodies: type-specific and cross-reactive determinants identified by immunofluorescence. Am J Trop Med Hyg. 1984 Jul; 33(4):695-8.
    View in: PubMed
    Score: 0.004
  38. Variation in infectivity of Saint Louis encephalitis viral strains for Culex pipiens quinquefasciatus (Diptera: Culicidae). J Med Entomol. 1983 Oct 05; 20(5):526-33.
    View in: PubMed
    Score: 0.004
  39. Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy. Lab Invest. 1983 Apr; 48(4):399-410.
    View in: PubMed
    Score: 0.004
  40. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein. Virology. 1983 Feb; 125(1):8-17.
    View in: PubMed
    Score: 0.004
  41. Fluorescent antibody techniques applied to the identification of dengue virus in infected tissue. Acta Virol. 1982 Sep; 26(5):376-81.
    View in: PubMed
    Score: 0.004
  42. Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect Immun. 2002 Sep; 70(9):5096-106.
    View in: PubMed
    Score: 0.004
  43. Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones. FEMS Immunol Med Microbiol. 2001 Mar; 30(2):157-65.
    View in: PubMed
    Score: 0.003
  44. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol. 2001 Jan; 75(2):934-42.
    View in: PubMed
    Score: 0.003
  45. Variation in virulence for mice and rhesus monkeys among St. Louis encephalitis virus strains of different origin. Am J Trop Med Hyg. 1980 Sep; 29(5):948-62.
    View in: PubMed
    Score: 0.003
  46. Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus. Protein Eng. 1999 Apr; 12(4):357-62.
    View in: PubMed
    Score: 0.003
  47. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun. 1999 Feb; 67(2):527-38.
    View in: PubMed
    Score: 0.003
  48. Necrotizing myocarditis in mice infected with Western equine encephalitis virus: Clinical, electrocardiographic, and histopathologic correlations. J Infect Dis. 1978 Jul; 138(1):59-66.
    View in: PubMed
    Score: 0.003
  49. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine. 1997 Mar; 15(4):370-6.
    View in: PubMed
    Score: 0.003
  50. Cloning, expression and functional activities of a single chain antibody fragment directed to fusion protein of respiratory syncytial virus. Immunotechnology. 1996 Sep; 2(3):219-28.
    View in: PubMed
    Score: 0.003
  51. Specific amplification by PCR of rearranged genomic variable regions of immunoglobulin genes from mouse hybridoma cells. PCR Methods Appl. 1995 Apr; 4(5):256-64.
    View in: PubMed
    Score: 0.002
  52. Lassa fever: review of epidemiology and epizootiology. Bull World Health Organ. 1975; 52(4-6):577-92.
    View in: PubMed
    Score: 0.002
  53. Recent isolations of Lassa virus from Nigerian rodents. Bull World Health Organ. 1975; 52(4-6):609-13.
    View in: PubMed
    Score: 0.002
  54. Western equine encephalomyelitis: virulence markers and their epidemiologic significance. Am J Trop Med Hyg. 1993 Sep; 49(3):322-8.
    View in: PubMed
    Score: 0.002
  55. Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances. J Nat Prod. 1992 Nov; 55(11):1569-81.
    View in: PubMed
    Score: 0.002
  56. Synthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride. J Med Chem. 1992 Aug 21; 35(17):3231-8.
    View in: PubMed
    Score: 0.002
  57. Characterization of viruses (Witwatersrand and Germiston) isolated from mosquitoes and rodents collected near Lunyo Forest, Uganda, in 1968. Arch Gesamte Virusforsch. 1972; 38(2):125-32.
    View in: PubMed
    Score: 0.002
  58. Effects of thorotrast on humoral antibody, viral multiplication, and interferon during infection with St. Louis encephalitis virus in mice. J Infect Dis. 1971 Mar; 123(3):297-300.
    View in: PubMed
    Score: 0.002
  59. Attenuation of wild-type yellow fever virus by passage in HeLa cells. J Gen Virol. 1990 Oct; 71 ( Pt 10):2301-6.
    View in: PubMed
    Score: 0.002
  60. Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue. J Gen Virol. 1988 Aug; 69 ( Pt 8):1921-9.
    View in: PubMed
    Score: 0.001
  61. Human infections with Tensaw virus in south Florida: evidence that Tensaw virus subtypes stimulate the production of antibodies reactive with closely related Bunyamwera serogroup viruses. Am J Trop Med Hyg. 1988 Jul; 39(1):117-22.
    View in: PubMed
    Score: 0.001
  62. Arbovirus investigations in Argentina, 1977-1980. II. Arthropod collections and virus isolations from Argentine mosquitoes. Am J Trop Med Hyg. 1985 Sep; 34(5):945-55.
    View in: PubMed
    Score: 0.001
  63. Arbovirus investigations in Argentina, 1977-1980. III. Identification and characterization of viruses isolated, including new subtypes of western and Venezuelan equine encephalitis viruses and four new bunyaviruses (Las Maloyas, Resistencia, Barranqueras, and Antequera). Am J Trop Med Hyg. 1985 Sep; 34(5):956-65.
    View in: PubMed
    Score: 0.001
  64. Identification of a new Venezuelan equine encephalitis virus from Brazil. Am J Trop Med Hyg. 1982 Nov; 31(6):1260-72.
    View in: PubMed
    Score: 0.001
  65. Characterization of Fort Morgan virus, an alphavirus of the western equine encephalitis virus complex in an unusual ecosystem. Am J Trop Med Hyg. 1980 Nov; 29(6):1428-40.
    View in: PubMed
    Score: 0.001
  66. Variation among strains of St. Louis encephalitis virus: basis for a genetic, pathogenetic, and epidemiologic classification. Ann N Y Acad Sci. 1980; 354:219-37.
    View in: PubMed
    Score: 0.001
  67. Tataguine virus infection in mice and hamsters. Microbios. 1980; 27(108):89-96.
    View in: PubMed
    Score: 0.001
  68. Arbovirus studies in Nupeko forest, a possible natural focus of yellow fever virus in Nigeria. II. Entomological investigations and viruses isolated. Trans R Soc Trop Med Hyg. 1974; 68(1):39-43.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.